No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects
- 603 Downloads
Rosuvastatin disposition is modulated by the expression and activity of several membrane transporters including BCRP (ABCG2). The objective of our study was to investigate the effects of pantoprazole, a previously proposed BCRP inhibitor, on the disposition of rosuvastatin.
The impact of pantoprazole (40 mg ID for 2 days) on rosuvastatin pharmacokinetics was evaluated in healthy volunteers (n = 16) who received a single oral dose of rosuvastatin (10 mg) either alone or with pantoprazole. Rosuvastatin, N-desmethylrosuvastatin, and rosuvastatin lactone levels were quantified in plasma while rosuvastatin and N-desmethylrosuvastatin excretion were measured in urine.
Ratios and 90 % standard confidence interval of geometric means for C max (1.03 [0.91–1.16]), AUC0–∞ (1.03 [0.89–1.19]) and renal clearance (0.96 [0.85–1.09]) were all within the pre-specified range of 0.8–1.25, indicating a lack of drug-drug interaction between pantoprazole and rosuvastatin.
Concomitant administration of pantoprazole with rosuvastatin did not affect rosuvastatin plasma concentrations. The use of pantoprazole as a BCRP inhibitor should be revisited when characterizing BCRP-mediated transport in humans.
KeywordsRosuvastatin Pantoprazole BCRP ABCG2 Transporters Pharmacokinetics Drug interaction
We acknowledge the contribution of Ms. Suzanne Dallaire, Ms. Hélène Langelier, and Ms. Suzanne Bordeleau (Research Group on Diabetes and Metabolic Regulation, CRCHUM Department of Medicine, Université de Montréal, Montréal, Quebec, Canada). We also acknowledge the contribution of Ms. Jocelyne Doucet and Ms. Mélissa Nelson.
This project was supported by internal funding obtained from the Fondation du CHUM. Jade Huguet was subsequently the recipient of a studentship from the Canadian Institutes of Health Research (CIHR) and the Fonds de Recherche Santé Québec (FRSQ). Jennifer Lu is the recipient of a studentship from the Fonds de Recherche Santé Québec (FRSQ). Veronique Michaud is the recipient of a research scholarship from FRQS in partnership with the Institut national d’excellence en santé et en services sociaux (INESSS).
Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work: Huguet J., Lu J., Gaudette F., Chiasson J.-L., Hamet P., Michaud V., Turgeon J.
Drafting the work or revising it critically for important intellectual content: Huguet J., Gaudette F., Chiasson J.-L., Hamet P., Michaud V., Turgeon J.
Final approval of the version to be published: Huguet J., Lu J., Gaudette F., Chiasson J.-L., Hamet P., Michaud V., Turgeon J.
Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: Huguet J., Lu J., Gaudette F., Chiasson J.-L., Hamet P., Michaud V., Turgeon J.
Compliance with ethical standards
The project was approved by the Ethic Committee of the CHUM Research Center (Trial #09.252), University of Montreal and the competent authority in Canada (Control Number #138105). Informed consent was obtained from all individual participants included in the study.
Disclosure of potential conflicts of interest
All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years ; no other relationships or activities that could appear to have influenced the submitted work.
- 13.Elsby R, Martin P, Surry D, Sharma P, Fenner K (2016) Solitary inhibition of the breast cancer resistance protein efflux transporter results in a clinically significant drug-drug interaction with rosuvastatin by causing up to a 2-fold increase in statin exposure. Drug Metab Dispos 44(3):398–408CrossRefPubMedGoogle Scholar
- 14.Camenish G, Riede J, Kunze A, Huwyler J, Poller B, Umehara K (2015) The extended clearance model and its use for the interpretation of hepatobiliary elimination data. ADMET & DMPK 3(1):1–14Google Scholar
- 15.Pham PA, la Porte CJL, Lee LS, van Heeswijk R, Sabo JP, Elgadi MM, Piliero PJ, Barditch-Crovo P, Fuchs E, Flexner C, Cameron DW (2009) Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 53(10):4385–4392CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Romaine SPR, Bailey KM, Hall AS, Balmforth AJ (2009) The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharm J 10(1):1–11Google Scholar
- 28.Tiberg M, Dudley A, Ungell A (2004) Regional and pH dependent permeability of rosuvastatin. In: AAPS 2004ed. AAPS journal, pp, T 2202.Google Scholar
- 29.Nakayama T, Maeda K, Fukizawa S, Kato Y, Dawson PA, Kusuhara H (2014) Characterization of the secretory transport of drugs in the mouse small intestine using Ussing chamber system. In: 19th North American ISSX 2014 (International Society for the Study of Xenobiotics) ed. International Society for the Study of Xenobiotics, pp, P 16.Google Scholar